Reliable Active Pharmaceutical Ingredient Manufacturer Supporting Global Healthcare

Clascoterone (cortexolone 17α-propionate, CB-03-01) is a first-in-class topical androgen receptor antagonist with a peripherally selective mechanism of action. Structurally, Clascoterone is a synthetic steroid derived from cortexolone (11-deoxycortisol), featuring a propionate ester at the C17α position and a 2-hydroxyacetyl side chain at C17. This unique molecular architecture enables Clascoterone to act as a potent androgen antagonist that is rapidly metabolized upon systemic absorption, thereby limiting systemic androgenic or antiandrogenic effects while maintaining robust local activity in the skin.

Abrocitinib is a small-molecule Janus kinase (JAK) 1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. Chemically, Abrocitinib selectively inhibits JAK1, modulating the JAK-STAT signalling pathway that plays a key role in the pathogenesis of atopic dermatitis. As the active pharmaceutical ingredient in CIBINQO®, Abrocitinib provides a targeted oral therapy for patients who are candidates for systemic therapy.

Sebetralstat is a potent and selective small-molecule plasma kallikrein inhibitor developed as the first oral, on-demand treatment for acute attacks of hereditary angioedema (HAE) . Chemically, Sebetralstat (also known as KVD900) inhibits plasma kallikrein, the enzyme responsible for converting high-molecular-weight kininogen to bradykinin, the key mediator of angioedema .

Pritelivir is a first-in-class, orally bioavailable viral helicase-primase inhibitor in development for the treatment of herpes simplex virus (HSV) infections, particularly in immunocompromised patients with acyclovir-refractory disease . Chemically, Pritelivir targets the viral helicase-primase complex, a novel mechanism of action distinct from nucleoside analogues like acyclovir .

Tezacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector that is a key component of the triple-combination therapy TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor) for the treatment of cystic fibrosis in patients with at least one F508del mutation . Chemically, Tezacaftor functions as a CFTR corrector, improving the processing and trafficking of defective CFTR proteins to the cell surface.

Linerixibat is an oral, minimally absorbed ileal bile acid transporter (IBAT) inhibitor developed for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC) . Chemically, Linerixibat inhibits the ileal bile acid transporter, reducing bile acid reabsorption and thereby decreasing systemic bile acid levels, which are associated with the pruritus experienced by PBC patients .